Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q2 2024 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Aug 01, 2024 / 12:30PM GMT
Release Date Price: €5.13 (-4.83%)
Operator

Good day, ladies and gentlemen. Welcome to Aurinia Pharmaceuticals second quarter 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded. I would like to turn the conference over to your host, Andrea Christopher, Head of Corporate Communications and Investor Relations for Aurinia Pharmaceuticals. Thank you. You may begin.

Andrea Christopher
Aurinia Pharmaceuticals Inc - Head of Corporate Communications and Investor Relations

Thank you, operator. And thank you to everyone for joining today's call and webcast. Joining me on the call this morning are Peter Greenleaf, Aurinia's Chief Executive Officer; Joe Miller, our Chief Financial Officer, and Dr. Greg Keenan, our Chief Medical Officer. Today, we will review and discuss Aurinia's 2024 second quarter financial and operational results as communicated in the company's press release issued this morning.

The company also filed its quarterly financial statements on Form 10-Q this morning. For more information, please refer to Aurinia's filings with the US Securities and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot